Metsera (MTSR) Competitors $35.97 -1.28 (-3.44%) As of 03:04 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MTSR vs. ASND, VTRS, RDY, QGEN, BBIO, MRNA, VRNA, ELAN, ROIV, and RVMDShould you be buying Metsera stock or one of its competitors? The main competitors of Metsera include Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Metsera vs. Its Competitors Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Qiagen BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Revolution Medicines Metsera (NASDAQ:MTSR) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk. Which has better earnings and valuation, MTSR or ASND? Metsera has higher earnings, but lower revenue than Ascendis Pharma A/S. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetseraN/AN/A-$209.13MN/AN/AAscendis Pharma A/S$490.75M24.48-$409.12M-$5.16-38.04 Do analysts prefer MTSR or ASND? Metsera presently has a consensus target price of $63.50, indicating a potential upside of 76.54%. Ascendis Pharma A/S has a consensus target price of $244.36, indicating a potential upside of 24.49%. Given Metsera's stronger consensus rating and higher possible upside, equities research analysts clearly believe Metsera is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metsera 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Ascendis Pharma A/S 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor MTSR or ASND? In the previous week, Metsera had 17 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 31 mentions for Metsera and 14 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.30 beat Metsera's score of 0.87 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metsera 9 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 10 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is MTSR or ASND more profitable? Metsera has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -54.94%. Company Net Margins Return on Equity Return on Assets MetseraN/A N/A N/A Ascendis Pharma A/S -54.94%N/A -24.31% SummaryMetsera beats Ascendis Pharma A/S on 7 of the 10 factors compared between the two stocks. Get Metsera News Delivered to You Automatically Sign up to receive the latest news and ratings for MTSR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTSR vs. The Competition Export to ExcelMetricMetseraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.78B$3.15B$5.82B$10.17BDividend YieldN/A2.32%5.69%4.60%P/E RatioN/A21.4374.6725.98Price / SalesN/A256.94454.5485.61Price / CashN/A45.3337.0859.91Price / Book-14.629.6512.186.31Net Income-$209.13M-$53.29M$3.29B$270.86M7 Day Performance0.28%0.44%1.08%3.46%1 Month Performance16.48%9.06%7.32%6.57%1 Year PerformanceN/A13.13%63.11%28.39% Metsera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTSRMetseraN/A$35.97-3.4%$63.50+76.5%N/A$3.78BN/A0.0081Trending NewsAnalyst ForecastAnalyst RevisionASNDAscendis Pharma A/S3.1612 of 5 stars$205.91+3.9%$244.36+18.7%+75.0%$12.60B$490.75M-39.911,017Positive NewsVTRSViatris1.6727 of 5 stars$10.50+1.6%$10.40-1.0%-10.3%$12.04B$14.74B-3.6232,000RDYDr. Reddy's Laboratories2.484 of 5 stars$14.34+1.3%$16.95+18.2%-7.1%$11.81B$3.81B21.7227,811Positive NewsQGENQiagen4.453 of 5 stars$47.54+1.1%$49.69+4.5%+3.3%$10.46B$1.98B28.085,765Positive NewsBBIOBridgeBio Pharma4.4486 of 5 stars$53.38+3.0%$63.35+18.7%+87.9%$9.91B$221.90M-13.05400Positive NewsAnalyst ForecastMRNAModerna4.5036 of 5 stars$25.14+3.5%$42.88+70.6%-68.1%$9.45B$3.24B-3.345,800Positive NewsVRNAVerona Pharma PLC American Depositary Share2.1652 of 5 stars$106.31+0.1%$109.00+2.5%+252.9%$9.19B$42.28M-107.3830Positive NewsHigh Trading VolumeELANElanco Animal Health2.6335 of 5 stars$18.40+5.3%$17.33-5.8%+29.8%$8.68B$4.44B21.399,000Positive NewsROIVRoivant Sciences2.9462 of 5 stars$12.92+2.8%$16.38+26.7%+16.4%$8.58B$29.05M-18.46860News CoveragePositive NewsOptions VolumeRVMDRevolution Medicines4.2417 of 5 stars$40.50+4.0%$72.00+77.8%+11.0%$7.28B$11.58M-9.00250Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies ASND Alternatives VTRS Alternatives RDY Alternatives QGEN Alternatives BBIO Alternatives MRNA Alternatives VRNA Alternatives ELAN Alternatives ROIV Alternatives RVMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTSR) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredElon’s new AI play could hand regular Americans a Tesla‑like paydayElon Musk just launched his boldest AI project yet... And if history is any guide — it could make early inv...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metsera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metsera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
